BioAdaptives, Inc.

What they do

BioAdaptives investigates, markets, and distributes natural plant, algal, and cyanobacteria-based products and medical devices for human and animal health, focused on nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral benefits. Human products in development include MyndMed for cognitive performance, MyndRenew, Zeranovia for weight loss, and Xcellara for regenerative wellness. The company also markets the FDA-cleared Class II Lung Flute device and, beginning April 2025, launched the PawPa Regen canine chew. Manufacturing is outsourced, and the company is reformulating its entire product line, having begun bringing out new products in the second quarter of 2025.

Revenue drivers

• Reformulated product line (human supplements) — New human products including MyndMed, MyndRenew, Zeranovia, and Xcellara began launching from the second quarter of 2025; overall annual revenue remained minimal at $18,278 in 2025, so no individual product is broken out in the filings.
• Lung Flute / Lung Cleanser medical device — BioAdaptives holds a marketing agreement for this FDA-cleared Class II device and in April 2024 assumed the sole owner's existing stock and rights to all future activities; the company states it intends to expand sales to medical communities, pharmacies, gyms, athletic clubs, and senior communities in the U.S. and internationally.
• PawPa Regen canine product — The company completed preparations to launch the PawPa Regen dog chew in April 2025; management describes it as a new standard in pet care, but no revenue contribution is separately disclosed.

Recent performance

Full-year 2025 revenue was $18,278, down from $12,669 in 2024 (the reported annual series shows 2024 revenue of $12,669), while the net loss widened to $1.6 million in 2025 from $899,161 in 2024. Operating cash flow was negative $516,025 in 2025, versus negative $249,517 in 2024. Recent quarterly revenue was $4,632 (Sept. 2025), $10,427 (Dec. 2025), $5,514 (March 2026), and $4,988 (June 2026). At June 30, 2026, total assets were $78,767, total liabilities were $1.8 million, shareholders' equity was negative $1.8 million, and cash and equivalents were $29,221.

Strategy

BioAdaptives is reformulating its entire product line and bringing out new products, starting in the second quarter of 2025. It completed the pre-launch phase of MyndMed in November 2025 and launched the PawPa Regen canine chew in April 2025. The company intends to expand Lung Flute/Lung Cleanser sales beyond direct selling to medical communities, pharmacies, gyms, athletic clubs, and senior communities in the U.S. and internationally, and is exploring agreements with other medical device manufacturers and intellectual property owners. Management states the company relies on external financing to maintain the corporate entity and will require additional financing to become commercially viable.

Risks

• Limited operating history and prior failed business plans — The company was incorporated in 2013 and cautions that it was unsuccessful at previous business plans, with purchased FHI and BioSwan products and technology not significantly exploited by their prior owners.
• No cash flows to support operations — The company states it has no cash flows to support operations and relies on external sources to maintain the corporate entity, with cash and equivalents of only $29,221 at June 30, 2026.
• Revenue insufficient to cover expenses — Product sales have not covered operating, public-company, research, and marketing expenses, and the company says it will require additional financing to become commercially viable.
• New products still in development — Management noted that as of the period ended December 31, 2024, its new products were still in development stage and would not be on market until the first or second quarter of 2025.

Outlook

Management says the company believes it will become commercially viable, generate significant revenues, and operate at a profit in future periods, but provides no assurances that it will meet those expectations. The company expects its reformulated product line, launched from the second quarter of 2025, and expanded Lung Flute distribution to drive sales. Its continued existence depends on implementing the business plan, generating sufficient cash flows from operations, and retiring existing liabilities on time.